27965933|t|Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome
27965933|a|Personalized therapy of colorectal cancer is influenced by morphological, molecular, and host-related factors. Here, we report the comprehensive clinicopathological and molecular analysis of an extra-gestational colorectal choriocarcinoma in a patient with probable Lynch syndrome. A 61-year-old female with history of gastric cancer at age 36 presented with a transmurally invasive tumor of the right hemicolon and liver metastasis. A right hemicolectomy was performed. Histopathological analysis showed a mixed trophoblastic and syncytiotrophoblastic differentiation, consistent with choriocarcinoma. Disease progression was rapid under oxaliplatin, capecitabine, irinotecan, and bevacizumab. Molecular phenotyping identified loss of mismatch-repair protein immunostaining for PMS2, microsatellite instability, a lack of MLH1 promoter methylation, and lack of BRAF mutation suggestive of Lynch syndrome. Targeted next-generation sequencing revealed an ataxia telangiectasia mutated (p.P604S) missense mutation. A bleomycin, etoposide, and cisplatin treatment protocol targeting germ cell neoplasia lead to disease remission and prolonged survival of 34 months. Comprehensive immunohistochemical and genetic testing is essential to identify uncommon cancers possibly related to Lynch syndrome. For rare tumors, personalized therapeutic approaches should take both molecular and morphological information into account.
27965933	0	26	Colorectal Choriocarcinoma	T191	C0009402
27965933	32	39	Patient	T101	C0030705
27965933	45	53	Probable	T081	C0033204
27965933	54	68	Lynch Syndrome	T047	C2931459
27965933	69	81	Personalized	T080	C1709510
27965933	82	89	therapy	T061	C0087111
27965933	93	110	colorectal cancer	T191	C1527249
27965933	128	141	morphological	T080	C0332437
27965933	143	152	molecular	T080	C1521991
27965933	158	170	host-related	T001	C1167395
27965933	200	213	comprehensive	T080	C1880156
27965933	214	233	clinicopathological	T169	C1521733
27965933	238	256	molecular analysis	T063	C1513380
27965933	263	280	extra-gestational	T040	C0032961
27965933	281	307	colorectal choriocarcinoma	T191	C0009402
27965933	313	320	patient	T101	C0030705
27965933	326	334	probable	T081	C0033204
27965933	335	349	Lynch syndrome	T047	C2931459
27965933	365	371	female	T032	C0086287
27965933	377	387	history of	T033	C0262926
27965933	388	402	gastric cancer	T191	C0024623
27965933	443	457	invasive tumor	T191	C0677898
27965933	465	480	right hemicolon	T023	C1305188
27965933	485	501	liver metastasis	T191	C0494165
27965933	505	524	right hemicolectomy	T061	C0192861
27965933	540	566	Histopathological analysis	T169	C0243140
27965933	576	595	mixed trophoblastic	T191	C0041182
27965933	600	621	syncytiotrophoblastic	T018	C1135936
27965933	622	637	differentiation	UnknownType	C0678724
27965933	639	654	consistent with	T078	C0332290
27965933	655	670	choriocarcinoma	T191	C0008497
27965933	672	691	Disease progression	T046	C0242656
27965933	708	719	oxaliplatin	T109,T121	C0069717
27965933	721	733	capecitabine	T114,T121	C0671970
27965933	735	745	irinotecan	T109,T121	C0123931
27965933	751	762	bevacizumab	T116,T121,T129	C0796392
27965933	764	785	Molecular phenotyping	T059	C1285572
27965933	805	828	mismatch-repair protein	T116,T123	C1333235
27965933	829	843	immunostaining	T059	C0487602
27965933	848	852	PMS2	T116,T123	C1333235
27965933	854	880	microsatellite instability	T046	C0920269
27965933	884	917	lack of MLH1 promoter methylation	T059	C3862821
27965933	931	944	BRAF mutation	T049	C1511021
27965933	959	973	Lynch syndrome	T047	C2931459
27965933	984	1010	next-generation sequencing	T090	C3274765
27965933	1023	1062	ataxia telangiectasia mutated (p.P604S)	T116,T126	C3711796
27965933	1063	1080	missense mutation	T045	C0599155
27965933	1084	1093	bleomycin	T116,T195	C0005740
27965933	1095	1104	etoposide	T109,T121	C0015133
27965933	1110	1119	cisplatin	T121,T197	C0008838
27965933	1120	1138	treatment protocol	T061	C0040808
27965933	1139	1148	targeting	T169	C1521840
27965933	1149	1168	germ cell neoplasia	T191	C4021985
27965933	1177	1194	disease remission	T033	C0544452
27965933	1199	1208	prolonged	T079	C0439590
27965933	1209	1217	survival	T052	C0038952
27965933	1232	1245	Comprehensive	T080	C1880156
27965933	1246	1265	immunohistochemical	T059	C1441616
27965933	1270	1285	genetic testing	T059	C0393006
27965933	1311	1327	uncommon cancers	T047	C4054123
27965933	1348	1362	Lynch syndrome	T047	C2931459
27965933	1368	1379	rare tumors	T047	C4054123
27965933	1381	1393	personalized	T080	C1709510
27965933	1394	1416	therapeutic approaches	T061	C0087111
27965933	1434	1443	molecular	T080	C1521991
27965933	1448	1461	morphological	T080	C0332437
27965933	1462	1473	information	T078	C1533716